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Abstract
Objectives To determine the effect of human papillomavirus (HPV)
quadrivalent vaccine on the risk of developing subsequent disease after
an excisional procedure for cervical intraepithelial neoplasia or diagnosis
of genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial
neoplasia.
Design Retrospective analysis of data from two international, double
blind, placebo controlled, randomised efficacy trials of quadrivalent HPV
vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)).
Setting Primary care centres and university or hospital associated health
centres in 24 countries and territories around the world.
Participants Among 17 622 women aged 15–26 years who underwent
1:1 randomisation to vaccine or placebo, 2054 received cervical surgery
or were diagnosed with genital warts, vulvar intraepithelial neoplasia, or
vaginal intraepithelial neoplasia.
Intervention Three doses of quadrivalent HPV vaccine or placebo at
day 1, month 2, and month 6.
Main outcome measures Incidence of HPV related disease from 60
days after treatment or diagnosis, expressed as the number of women
with an end point per 100 person years at risk.
Results A total of 587 vaccine and 763 placebo recipients underwent
cervical surgery. The incidence of any subsequent HPV related disease
was 6.6 and 12.2 in vaccine and placebo recipients respectively (46.2%
reduction (95% confidence interval 22.5% to 63.2%) with vaccination).
Vaccination was associated with a significant reduction in risk of any
subsequent high grade disease of the cervix by 64.9% (20.1% to 86.3%).
A total of 229 vaccine recipients and 475 placebo recipients were
diagnosed with genital warts, vulvar intraepithelial neoplasia, or vaginal
intraepithelial neoplasia, and the incidence of any subsequent HPV
related disease was 20.1 and 31.0 in vaccine and placebo recipients
respectively (35.2% reduction (13.8% to 51.8%)).
Conclusions Previous vaccination with quadrivalent HPV vaccine among
women who had surgical treatment for HPV related disease significantly
reduced the incidence of subsequent HPV related disease, including
high grade disease.
Trial registrations NCT00092521 and NCT00092534
Correspondence to: E A Joura elmar.joura@meduniwien.ac.at
Extra material supplied by the author: Supplementary tables 1 and 2 showing effects of using 60 day or 90 day interval between initial surgery or
disease diagnosis and subsequent disease diagnoses on vaccine efficacy estimates (see
http://www.bmj.com/content/344/bmj.e1401?tab=related#webextra)
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Research
RESEARCHIntroduction
The currently available human papillomavirus (HPV) vaccines
that are based on recombinant virus-like particles are designed
to prevent HPV associated disease. Both the quadrivalent
vaccine (against HPV types 6, 11, 16, and 18) and the bivalent
vaccine (against types 16 and 18) are highly effective in
preventing cervical intraepithelial neoplasia grade II-III or
adenocarcinoma in situ in women who are not infected with the
relevant HPV type before vaccination.
1-5 The quadrivalent
vaccine has also been shown to prevent HPV related vulvar
intraepithelial neoplasia grade II-III, vaginal intraepithelial
neoplasiagradeII-III,andgenitalwartsinwomenandtoprevent
genital warts and high grade anal disease in men.
1 6-9
Current data show that HPV vaccination does not reduce
progression to cervical precancers in women with ongoing
infections at the time of vaccination.
5 10 11 However, no studies
to date have looked at the impact of HPV vaccination in
preventing subsequent disease after treatment for such
precancers. In two recent phase III clinical trials of the
quadrivalent HPV vaccine, more than 17 000 women were
followed for approximately four years. Participants who
underwent treatment for cervical, vulvar, or vaginal disease
continuedtobefolloweduntiltheendofthestudy.Wetherefore
had a unique opportunity to evaluate the post-treatment effect
of vaccination in these women. In this retrospective analysis
we identified women who had an excisional procedure for
cervical disease or who were diagnosed with genital warts,
vulvar intraepithelial neoplasia, or vaginal intraepithelial
neoplasiaafterrandomisationtovaccineorplaceboandfollowed
these women for additional disease outcomes. The objective of
this study was to determine if the vaccine decreased the risk of
developingsubsequentdiseaseafterthefirstdefinitivetreatment.
Methods
Objectives
The primary objective of this retrospective analysis was to
determinewhetheradministrationofquadrivalentHPVvaccine,
compared with placebo, reduced the incidence of subsequent
HPVrelateddiseaseamongwomenwhohadundergonesurgery
for cervical disease or who were diagnosed with vulvar or
vaginal disease (genital warts, vulvar intraepithelial neoplasia,
or vaginal intraepithelial neoplasia) after enrolment into the
FUTURE I or FUTURE II clinical trials (fig 1⇓). Subsequent
HPV related disease is defined as any disease that was detected
at least 60 days after treatment or diagnosis. We measured the
vaccine’s impact on end points that were associated with HPV
types6,11,16,and18specificallyandonendpointsirrespective
of causal HPV type.
Study population
Between December 2001 and May 2003, 17 622 women aged
15–26 years were enrolled in one of two randomised, double
blind,placebocontrolledtrials(FUTUREIandFUTUREII).
1 2
The studies were conducted in accordance with principles of
Good Clinical Practice and were approved by the appropriate
institutional review boards and regulatory agencies.
The study designs and the results of the primary hypotheses
have been described elsewhere.
1 2 Women were eligible to
participate if they were not pregnant, did not report previous
abnormalresultsonacervicalsmeartest,andhadhadalifetime
number of no more than four sex partners. Neither study
included HPV testing (DNA or serology testing) or clinical
examination before randomisation; thus, the trials allowed the
enrolment of women with ongoing HPV infection or disease.
Intervention
In both trials, participants were randomly assigned (1:1) to
receive intramuscular injections of quadrivalent HPV vaccine
(GardasilorSilgard,Merck,WhitehouseStation,NJ)orvisually
indistinguishable placebo at day 1, month 2, and month 6.
ComprehensiveanogenitalexaminationsandThinPrepcervical
cytology (Cytyc, Boxborough, MA, USA) were performed
during scheduled visits, which occurred every 6–12 months
after the vaccination phase.
1 2 Cytology specimens were
classified according to the Bethesda System 2001.
12 Women
reported any abnormality or suspected disease in between the
scheduled study visits. All participants were required to use
birth control during the vaccination phase (day 1 through to
month 7), and all participants were evaluated for pregnancy
before the administration of each dose of vaccine or placebo
with a human chorionic gonadotropin assay sensitive to 25
international units.
13 Counselling about safe sex and
contraceptive use was part of the study protocol.
Protocol specified guidelines were used to triage women with
smear test abnormalities to colposcopy.
1 2 Colposcopists were
trained to locate and biopsy all discrete abnormal areas on the
cervix and lower genital tract. Loop electrosurgical excision
was the preferred method for definitive therapy for cervical
intraepithelial neoplasia grade II-III, adenocarcinoma in situ,
and persistent cervical intraepithelial neoplasia grade I.
However, other methods included cervix conisation,
cryotherapy, and electrocauterisation. The frequencies of each
techniquerecordedwereloopelectrosurgicalexcision(84.7%),
cervical conisation (12.5%), cryotherapy (0.7%), and other
(2.1%). As loop electrosurgical excision and cervix conisation
accounted for 97.2% of the procedures performed, with no
difference between the treatment groups (97.1% with placebo,
97.4% with vaccine) we use the term “cervical surgery” to
describeanymethodusedtotreatcervicaldisease.Management
of vulvar or vaginal disease followed the investigational site’s
standards and practice and included surgical or topical therapy.
Population for retrospective subanalysis
In this retrospective, intention to treat analysis, we identified
all women who underwent definitive cervical therapy or who
were diagnosed with vulvar or vaginal disease in the pooled
FUTURE I and II studies after being randomised to and
receiving at least one dose of HPV vaccine or placebo. The
incidenceratesforsubsequentdiseasewerecalculatedwithcase
counting starting 60 days after cervical surgery or diagnosis of
vulvar or vaginal disease.
Rationale for 60 day window to define
subsequent disease
As stated previously, women were referred for colposcopy and
cervical surgery in accordance with a triage algorithm.
1 2 In
FUTURE I, the pre-specified primary end points included all
HPVrelatedanogenitaldisease,thusthestudyincludedstringent
criteriafordiseasedeterminationandfollow-up,includingmore
frequent examinations and screening and more aggressive
colposcopy triage for suspected disease. In FUTURE II, the
primary end point was cervical intraepithelial neoplasia grade
II-IIIandadenocarcinomainsitu.Treatmentofvulvarorvaginal
disease in FUTURE II was based on local standards of care,
and the investigators were not required to record the date or
method of treatment. We therefore examined the average time
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RESEARCHfrom diagnosis to treatment of genital warts, vulvar
intraepithelial neoplasia, and vaginal intraepithelial neoplasia
within the FUTURE I study. That information was used to
determine an appropriate time frame after which most women
would have been treated, so that follow-up after that window
would probably capture new, rather than residual, disease. In
FUTURE I, the mean number of days between diagnoses and
treatment of genital warts, vulvar intraepithelial neoplasia, and
vaginalintraepithelialneoplasiawas28days(interquartilerange
0–42 days). As the trials were less than four years of total
duration (mean of 3.6 years), and since 82% had treatment
within60daysofthepathologypaneldiagnosis,wechoosethis
as the cut off to ensure there would be enough follow-up time
to detect subsequent disease after treatment. We assumed a
similar time window between treatment and diagnosis in
FUTURE II, and used the same window (60 days after
diagnosis) for both studies. For consistency, the same time
window was applied for counting subsequent disease after
cervicalsurgery.Asensitivityanalysiswasalsoperformedusing
a 90 day time window, as 91% of subjects had treatment within
90 days.
Efficacy end points and statistics
All specimens from biopsies and excisional procedures were
tested for 14 HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 59) using an assay based on the polymerase
chain reaction.
14-16 All tissue specimens underwent
histopathological review by a pathology panel, who were
masked to the women’s vaccination group and HPV status. A
woman was considered to have developed an end point related
to vaccine HPV types (HPV 6, 11, 16, or 18) or an end point
related to 10 non-vaccine types (HPV 31, 33, 35, 39, 45, 51,
52, 56, 58, or 59) if the respective HPV DNA were detected in
the same lesion that was diagnosed by the pathology panel as
cervicalintraepithelialneoplasia,vulvarintraepithelialneoplasia,
vaginal intraepithelial neoplasia, or genital warts. For analyses
of all disease, irrespective of causal HPV type, a woman was
considered to have developed an end point if she had a lesion
diagnosedbythepathologypanelwithoutconsiderationofHPV
status.
Intheanalyses(presentedintables2–4⇓⇓⇓)awomaniscounted
only once for each end point (that is, once in each row), but a
woman may have developed more than one end point during
the trial (that is, a women may appear in more than one row).
For example, a woman who is diagnosed with a cervical
intraepithelial grade 3 lesion that is positive to HPV types 16,
31, and 45 would be counted once for (1) any disease; (2) any
cervical disease; (3) any cervical intraepithelial grade II or
worse; (4) any cervical intraepithelial grade III or worse; (5)
any disease related to vaccine HPV types; (6) cervical
intraepithelial grade I or worse related to vaccine HPV types;
(7) cervical intraepithelial grade II or worse related to vaccine
HPV types; and (8) cervical intraepithelial grade III or worse
related to vaccine HPV types.
Women contributed to person years at risk from 60 days after
the initial surgery or diagnosis until the day of ascertainment
of the subsequent disease end point, or, for those without a
subsequentdiseaseendpoint,untilthedayoftheirlastfollow-up
visit. Incidence, or rate of subsequent disease, is expressed as
the number of women with an end point per 100 person years
at risk. A point estimate of vaccine efficacy (that is, percentage
reduction of the relative end point) and the 95% confidence
interval were calculated on the basis of the observed case split
betweenvaccineandplaceborecipients,adjustedfortheaccrued
person time in each group. The criterion for statistical
significance(P<0.05)wasequivalenttorequiringthatthelower
bound of the confidence interval for vaccine efficacy exclude
0%. An exact conditional procedure was used to evaluate
vaccineefficacyundertheassumptionthatthenumbersofcases
in the vaccine and placebo groups were independent Poisson
random variables.
17
Kaplan-Meier estimates (and 95% confidence intervals) of
cumulative incidence rates for subsequent disease were plotted
with case counting starting 60 days after cervical surgery or
vulvar or vaginal disease diagnosis.
18 The plots were not part
of a formal survival analysis; rather they give a visual
demonstration of the divergence of the incidence rates between
thetwovaccinationarmsovertime.The95%confidenceinterval
for the Kaplan-Meier incidence at intervals of six months are
notdirectlycomparablewithvaccineefficacyestimates.Vaccine
efficacy was calculated from the exact conditional procedure
and is included in the Kaplan-Meier plots as a reference.
Results
Analysis population
The FUTURE I and II trials collectively enrolled and
randomised 17 622 women. The populations analysed to
determine the impact of quadrivalent HPV vaccine on
subsequent disease is shown in fig 2⇓. Of the 1350 women
includedintheanalysis,onlyfive(threeplaceborecipients,two
vaccinerecipients)receivedfewerthanallthreedoses,withone
woman in the placebo group having only one dose, and the
others receiving two doses each. These women stopped the
vaccination phase because pregnancy (two women), lactation
(one), medical history (one), and unknown reason (one), but
continued the follow-up phase of the study.
Asexpected,moreplaceborecipientsunderwentcervicalsurgery
fordiseaseduetoanyHPVtype(n=763)thanvaccinerecipients
(n=587). Among women who underwent cervical surgery,
vaccine recipients had numerically higher baseline (at day 1 of
the study) prevalence of squamous intraepithelial lesions
(36.5%) compared with placebo recipients (30.0%) and higher
prevalence of HPV DNA (70.1%) than placebo (62.0%) (table
1⇓).Amongwomenwhohadadiagnosisofgenitalwarts,vulvar
intraepithelial neoplasia, or vaginal intraepithelial neoplasia,
vaccine recipients also had a higher baseline prevalence than
placebo recipients of squamous intraepithelial lesions (27.0%
v 14.2%) and HPV DNA (65.9% v 44.0%) and a lower
proportion of current or former smokers (36.7% v 43.4%).
Incidence of subsequent disease in placebo
group
Placebo recipients who were treated for HPV related disease in
these clinical trials were at increased risk for developing
subsequent HPV related disease (fig 3⇓). Within an average of
only 1.3 years after cervical surgery (maximum follow-up of
3.7 years), the incidence of any subsequent disease among
placebo recipients was 12.2 per 100 person years at risk, and
5.2%(31/593)developedsubsequenthighgradecervical,vulvar,
orvaginaldisease(incidenceof3.7).Comparedwiththosewho
underwent cervical surgery, those who were diagnosed with
genital warts, vulvar intraepithelial neoplasia, or vaginal
intraepithelial neoplasia had nearly three times the risk for
developing any subsequent HPV related disease (incidence of
31.0). Within an average of only 1.2 years after the initial
diagnosis of vulvar or vaginal disease (maximum follow-up of
4.0 years), 13.0% (55/422) developed high grade cervical,
vulvar, or vaginal disease (incidence of 8.4). For both analysis
populations, the incidence of subsequent low grade disease
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RESEARCH(genital warts; vulvar or vaginal or intraepithelial neoplasia
grade I; or cervical intraepithelial neoplasia grade I) was also
high (10.1 to 26.1).
Impact of prior vaccination on disease after
cervical surgery
Vaccination was associated with a significantly reduced risk of
any subsequent HPV related disease after cervical surgery,
irrespective of causal HPV type, by 46.2% (95% confidence
interval22.5%to63.2%)(table2⇓).Vaccinationwasassociated
with a significantly reduced risk of any subsequent cervical
disease (by 48.3% (95% confidence interval 19.1% to 67.6%)
for cervical intraepithelial neoplasia grade I or worse) and any
subsequenthighgradecervicaldisease(64.9%(20.1%to86.3%)
for cervical intraepithelial neoplasia grade II or worse). A
significant reduction in the incidence of genital warts was
observed (63.0% (10.3% to 86.6%)). Vaccination was also
associated with significantly reduced risk of any subsequent
diseaserelatedtovaccineHPVtypes(79.1%(49.4%to92.8%)).
The impact on vulvar or vaginal disease was primarily driven
by a reduction in the incidence of genital warts. Vaccine
recipients saw an 89.0% reduction (54.9% to 98.7%) in genital
warts related to vaccine HPV types after cervical surgery.
Vaccine efficacy estimates were similar in the sensitivity
analysis which used a 90 day interval between the first and
subsequent disease diagnoses (see supplementary table 1 on
bmj.com).
As shown in table 2⇓, two vaccine and nine placebo recipients
developed cervical disease related to vaccine HPV types after
their first cervical surgery. Of the two women in the vaccine
arm, one developed cervical intraepithelial neoplasia grade I
andIIlesionsrelatedtoHPVtype16aftersurgery.Thiswoman
was DNA positive to HPV types 16, 31, 56, and 58 at study
entry and had HPV types 16 and 58 detected in her original
surgical specimen. The second woman developed a cervical
intraepithelial neoplasia grade I lesion related to HPV 18. She
was DNA positive to HPV 18 at day 1 (and was negative to the
other 11 tested high risk HPV types) but underwent
electrocauterisation, so no surgical specimen existed. Of the
ninewomenintheplaceboarmwhodevelopedcervicaldisease
related to vaccine HPV types, six (67%) did not have the same
vaccine HPV type detected in their original surgical specimen.
Table 3⇓ shows the vaccine efficacy for cervical intraepithelial
neoplasiagradeIorworsedueto10highrisk,non-vaccineHPV
types after surgery for cervical disease. Vaccination was
associated with reduction of cervical intraepithelial neoplasia
grade I or worse associated with HPV31, 33, 45, 52, 58 (the
five most common HPV types found in cervical cancer after
HPV16andHPV18)by56.6%(3.4%to82.3%).Forindividual
HPV types, a significant reduction was observed for HPV31
(88.4%, [18.6% to 99.7%]). A positive percent reduction was
observed for seven of the other types analysed, though the data
did not reach statistical significance.
Fig 4⇓ shows the divergence of incidence rates over time for
any subsequent disease and any subsequent vulvar or vaginal
disease, irrespective of causal HPV type. Among both vaccine
and placebo recipients, the incidence of any subsequent HPV
related disease (fig 4A) had not reached a plateau by the end of
study, and the divergence of incidence between the vaccine
group and the placebo group increased at each six month
interval. In contrast, the incidence of subsequent vulvar or
vaginal disease after cervical surgery seemed to have reached
aplateauforbothvaccineandplaceborecipientsbyendofstudy
(fig 4B).
Impact of prior vaccination on disease after
diagnosis of genital warts or of vulvar or
vaginal intraepithelial neoplasia
Vaccination was associated with a reduced risk of any
subsequent HPV related disease, irrespective of causal HPV
type, by 35.2% (13.8% to 51.8%) (table 4⇓). For end points
related to vaccine HPV types, there was a 64.4% reduction
(41.6% to 79.3%) in any disease observed. Fig 4⇓ shows the
divergence of incidence rates over time for any subsequent
disease, and any subsequent cervical disease, irrespective of
causal HPV type. Among both vaccine and placebo groups, the
incidenceofanysubsequentdisease(fig4C)andanysubsequent
cervical disease (fig 4D) had not reached a plateau by end of
study.Vaccineefficacyestimatesweresimilarinthesensitivity
analysis which used a 90 day interval between initial surgery
or disease diagnosis and subsequent disease diagnoses
(supplementary table 2 on bmj.com).
Impact of prior vaccination on recurrent
genital warts and low grade disease
In the previous analyses, we considered the impact of
vaccination collectively among women who were diagnosed
with genital warts, vulvar intraepithelial neoplasia grade I or
worse, or vaginal intraepithelial neoplasia grade I or worse. If
weconsideronlythosewomenwhowerediagnosedwithgenital
warts, there were 134 vaccine and 351 placebo recipients,
respectively. The average time to the first detection of genital
warts in these women was 1.4 years in the vaccine group and
2.1yearsintheplacebogroup.Ofthesewomen,43.3%(58/134)
vaccine recipients and 14.8% (52/351) placebo recipients were
infected with HPV types 6 or 11 at study entry. When we
followed these women for recurrent genital warts, vaccination
was associated with less recurrence of genital warts related to
vaccine HPV types by 46.8% (10 cases in vaccine group v 33
cases in placebo group), but the reduction was not statistically
significant.
Asimilaranalysiswasperformedforrecurrentvulvarorvaginal
lowgradedisease(genitalwarts,vulvarintraepithelialneoplasia
gradeI,orvaginalintraepithelialneoplasiagradeI).Therewere
210 vaccine recipients and 445 placebo recipients who were
diagnosed with low grade disease. Vaccination was associated
with reduced risk of subsequent low grade disease related to
vaccine HPV types by 60.3% (21.7% to 81.5%).
Discussion
Ourresultsofthesubgroupanalysisdemonstratethatvaccination
withthequadrivalentHPVvaccinewasassociatedwithreduced
incidence of subsequent cervical, vulvar, and vaginal
intraepithelial neoplasia and genital warts in women who had
been diagnosed and treated for cervical and vulvar or vaginal
disease. After treatment for high grade cervical intraepithelial
neoplasia, women are at increased risk for cervical cancer in
thelongterm,
19andourdatashowtheyareatriskforsubsequent
diagnosesofpremalignantdiseaseintheshortterm.Withintwo
years after treatment, those with prior vaccination had
significantly reduced risk of subsequent high grade cervical
disease. Our analysis also shows that for women who were
diagnosed with HPV related vulvar or vaginal disease, those
with prior vaccination had significantly reduced risk of
developing any subsequent HPV related disease as well as
disease related to the vaccine HPV types (types 6, 11, 16, and
18). These are, to our knowledge, the first results in vaccinated
womenwhohaveundergonetreatmentforHPVrelateddiseases.
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RESEARCHStrengths of study
We took several steps to enhance the accuracy, reproducibility,
and generalisability of our findings. We considered all disease
end points, irrespective of causal HPV type. Histological
diagnoses were determined by a panel of expert gynaecologic
pathologistswhowereunawareofwomen’streatmentorhistory
of cervical or vulvar disease. Generalisability was enhanced by
enrolling women from both developed and developing nations
and by using standard management algorithms for treatment of
cervical disease and local standards of care for treatment of
vulvar or vaginal disease.
20 21
In addition to measuring the impact on precancerous lesions,
we also measured the impact on low grade disease. Although
low grade cervical and vulvar or vaginal lesions are considered
to be a morphological manifestation of an HPV infection, these
lesions contribute to the clinical and economic burden of HPV
disease. For example, the psychosocial
22-24 and economic
25 26
implications of genital warts are substantial and reflect, in part,
the high transmission and recurrence rates.
27-29 Lesion and
infection are a local phenomenon of the transformation zone at
the cervix, which is completely removed by treatment, whereas
vulvovaginal disease is a field infection (infectious areas are
not completely removed by the treatment and, therefore, the
recurrence rate is high). In contrast to breast and cervical
cancers, there are no screening programmes for vaginal and
vulvar malignancies, and precursors of vulvar and vaginal
cancers are often not recognised.
7 Cervical, vulvar, and vaginal
intraepithelialneoplasiagradeIandgenitalwartshavealsobeen
shown to contain a variety of high risk HPV types.
6 30-33 In this
study,thehighestratesofsubsequentdiseaseobservedwaslow
grade, and vaccination rapidly and significantly reduced the
onset of subsequent low grade lesions, particularly among
women who underwent cervical surgery.
Comparison with other studies
These data are in line with previous studies that suggest the
benefits of vaccination are not limited to the primary target
group of young, sexually naïve girls. In an intention to treat
analysis that measured the impact of the quadrivalent HPV
vaccine in a mixed population of HPV naïve and HPV infected
women, vaccination significantly reduced the number of
abnormalsmeartestresultsandproceduressuchascolposcopy,
biopsy examination, and definitive therapy irrespective of the
causal HPV type.
34 Another study has shown the quadrivalent
HPVvaccinegeneratesananamnesticresponse(renewedrapid
production of an antibody on a subsequent encounter with the
sameantigen)inwomenaged15–26whoareseropositivebefore
vaccination,
35 36andthatthequadrivalentHPVvaccineprevents
reinfection or reactivation of disease that is related to vaccine
HPV types.
37 For example, women who had cleared an HPV16
infectioninthepastwereprotectedfromdevelopingsubsequent
HPV16 related disease.
37 A previous study has shown that
women who are infected with one or more vaccine HPV types
derive residual benefit by the quadrivalent HPV vaccine’s
prevention of infection and disease from HPV type(s) to which
the woman has not yet been exposed.
38 The vaccine is also
effective in women up to the age of 45, whereby prophylactic
vaccine efficacy against disease related to vaccine HPV types
was 92.4% (49.6% to 99.8).
39 40
Limitations of study
Thisretrospectiveanalysisisaccompaniedbysomelimitations.
The trials were not designed or powered to evaluate the effects
of vaccination after cervical surgery or diagnosis. Women with
a prior history of HPV related disease were excluded from
enrolment, so we cannot directly measure the vaccine’s impact
in women who have undergone treatment before vaccination,
sinceallwomeninthisstudywerevaccinatedbeforetreatment.
Asasurrogate,weidentifiedwomenwhoweretreatedforHPV
related disease after randomisation and followed them for
additional disease outcomes. In this relatively low risk
population (healthy women with a mean of two lifetime sexual
partners and no prior history of HPV related disease) the risk
of subsequent disease after a diagnosis of HPV related vulvar
or vaginal disease was about three times higher than after
cervical surgery. Although the reasons for this are unclear, our
dataindicatethatwomenwhowerediagnosedwithHPVrelated
disease were a high risk group at study entry, as nearly half of
these women (44–70%) were infected with at least one of the
14 tested HPV types, and 14–37% had abnormal cytology at
day 1.
There was an imbalance in some baseline characteristics (that
is, at day 1) as a result of our selection of patients who had
treatment for cervical or vulvovaginal disease after vaccination
that may have potentially biased these results. Among women
who had a pathology panel diagnosis of vulvar or vaginal
disease, placebo recipients had a higher proportion of current
or former smokers (43.4%) compared with vaccine recipients
(36.7%), and women who smoke are about twice as likely as
non-smokers to get cervical cancer.
41 However, the most
important risk factor for cervical cancer is infection by HPV,
41
and, because of our subsetting to those who later received
treatmentforcervicalorvulvovaginaldisease,vaccinerecipients
had numerically higher day 1 prevalence of HPV DNA and day
1prevalenceofsquamousintraepitheliallesionscomparedwith
placebo recipients. In spite of these potential biases, there were
still significant reductions in subsequent disease for vaccine
recipients compared with placebo recipients.
It is important to note that most of the “first” disease detected
in both vaccine and placebo recipients was a result of these
infections that were present at day 1, and not due to vaccine
failure. It is also important to note that the impact of the vaccine
in preventing subsequent disease does not indicate that
vaccination provides a therapeutic effect. Though it is possible
thatsomeofthecervicaldiseasedetectedaftercervicaldefinitive
therapy is residual, these data suggest that most of the
subsequent disease is from an infection with an HPV type that
was not the causal type of the first lesion. For example, we
found that six of the nine women in the placebo arm who
developed cervical disease related to vaccine HPV types after
surgery had a vaccine HPV type that was not detected in the
originalsurgicalspecimen,suggestingthatthelesiondiagnosed
after surgery was from a new infection and not from residual
disease. Four of the six women in the placebo group who
developedcervicalintraepithelialneoplasiarelatedtoavaccine
HPV type after surgery that was not in the original surgical
specimen also reported at least one new sexual partner in the
interval between the first cervical surgery and the subsequent
disease diagnosis. We have also previously shown that
vaccination of women who were negative to 14 HPV types at
enrolment reduced the incidence of cervical intraepithelial
neoplasia grade III or worse associated with 10 non-vaccine
HPVtypesby32.5%(6.0%to51.9%),andthepresentanalyses
suggest some of the subsequent disease that is prevented is due
toprotectionagainstHPVtypesthatarephylogeneticallyrelated
to vaccine HPV types (6, 11, 16, and 18).
42 Although the exact
underlying mechanism is not fully known, these observed
reductions are felt to be clinically significant.
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RESEARCHConclusions
Atpresent,intheUnitedStatesandothercountries,HPVtesting
before HPV vaccination is not recommended.
43 Data to date
indicateHPVvaccinationdoesnotreduceprogressiontocervical
pre-cancers in women with ongoing infection, and cervical
cancer screening and corresponding management should
continue as per local guidelines.
5 10 11 Our study confirms that
vaccination does not reduce progression to disease in women
who are infected with HPV at the time of vaccination, but
women who were treated for disease in the context of these
studies were at risk for developing subsequent disease, and
vaccination offered substantial benefit. Prophylactic HPV
vaccines have been shown to remain efficacious for at least 10
years,
44 and so it can be anticipated that vaccinated women will
continue to benefit from a reduction in disease risk in the long
term. However, only long term surveillance of vaccinated
populations can determine the population effectiveness of
vaccination.Severalprogrammestomonitorboththesafetyand
theimpactofHPVvaccinesondiseaseoutcomesareinplace.
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RESEARCHTables
Table 1| Characteristics at study enrolment (day 1) of women aged 15–26 years who had undergone cervical surgery or had a diagnosis
of vulvar or vaginal disease* after randomisation to quadrivalent HPV vaccine or placebo. Values are numbers (percentages) unless stated
otherwise
Women who had diagnosis of vulvar or vaginal disease* Women who had cervical surgery
Placebo (n=475) Vaccine (n=229) Placebo (n=763) Vaccine (n=587)
19.3 (2.1) 19.9 (1.9) 19.8 (2.0) 19.9 (2.0) Mean (SD) age (years)
Race or ethnicity:
14 (2.9) 6 (2.6) 18 (2.4) 15 (2.6) Asian
33 (6.9) 7 (3.1) 41 (5.4) 23 (3.9) Black
88 (18.5) 49 (21.4) 110 (14.4) 76 (12.9) Hispanic American
1 (0.2) 0 1 (0.1) 0 Native American
304 (64.0) 136 (59.4) 520 (68.2) 407 (69.3) White
35 (7.4) 31 (13.5) 73 (9.6) 66 (11.2) Other
Smoking status:
177 (37.3) 64 (27.9) 260 (34.1) 187 (31.9) Current
29 (6.1) 20 (8.7) 46 (6.0) 45 (7.7) Former
269 (56.6) 145 (63.3) 457 (59.9) 355 (60.5) Never
23 (4.8) 4 (1.7) 20 (2.6) 9 (1.5) Virgins
Non-virgins’ lifetime No of sexual partners:
123/452 (27.2) 64/225 (28.4) 179/743 (24.1) 117/578 (20.2) 1
132/452 (29.2) 60/225 (26.7) 201/743 (27.1) 148/578 (25.6) 2
97/452 (21.5) 51/225 (22.7) 168/743 (22.6) 143/578 (24.7) 3
83/452 (18.4) 41/225 (18.2) 174/743 (23.4) 156/578 (27.0) 4
17/452 (3.8) 9/225 (4.0) 21/743 (2.8) 14/578 (2.4) ≥5
2 2 2 3 Median
HPV infection and disease at baseline
66/464 (14.2) 61/226 (27.0) 225/749 (30.0) 208/570 (36.5) Squamous intraepithelial lesion present on
cytology:
17/464 (3.7) 16/226 (7.1) 65/749 (8.7) 47/570 (8.2) Atypical cells of undetermined significance
3/464 (0.6) 0/226 (0.0) 10/749 (1.3) 13/570 (2.3) Atypical cells, cannot exclude high grade lesion
45/464 (9.7) 42/226 (18.6) 120/749 (16.0) 112/570 (19.6) Low grade lesion
1/464 (0.2) 3/226 (1.3) 29/749 (3.9) 36/570 (6.3) High grade lesion
0/464 (0.0) 0/226 (0.0) 1/749 (0.1) 0/570 (0.0) Atypical glandular cells
208/473 (44.0) 151/229 (65.9) 471/760 (62.0) 410/585 (70.1) PCR positive for ≥1 HPV type at baseline†:
112/473 (23.7) 95/228 (41.7) 262/759 (34.5) 254/584 (43.5) Vaccine HPV type:
55/473 (11.6) 60/226 (26.5) 60/754 (8.0) 59/582 (10.1) HPV6
5/473 (1.1) 6/228 (2.6) 6/757 (0.8) 13/582 (2.2) HPV11
52/473 (11.0) 45/228 (19.7) 187/755 (24.8) 183/581 (31.5) HPV16
24/473 (5.1) 12/228 (5.3) 57/757 (7.5) 60/580 (10.3) HPV18
165/472 (35.0) 107/229 (46.7) 389/758 (51.3) 333/584 (57.0) Non-vaccine type:
31/471 (6.6) 17/228 (7.5) 96/755 (12.7) 78/577 (13.5) HPV31
13/472 (2.8) 5/228 (2.2) 44/754 (5.8) 32/582 (5.5) HPV33
13/472 (2.8) 7/228 (3.1) 40/752 (5.3) 32/582 (5.5) HPV45
41/472 (8.7) 23/228 (10.1) 102/755 (13.5) 79/581 (13.6) HPV52
25/472 (5.3) 10/228 (4.4) 81/757 (10.7) 62/581 (10.7) HPV58
9/472 (1.9) 8/229 (3.5) 29/756 (3.8) 39/581 (6.7) HPV35
30/472 (6.4) 21/228 (9.2) 71/753 (9.4) 68/580 (11.7) HPV39
44/472 (9.3) 34/227 (15.0) 112/752 (14.9) 101/581 (17.4) HPV51
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RESEARCHTable 1 (continued)
Women who had diagnosis of vulvar or vaginal disease* Women who had cervical surgery
Placebo (n=475) Vaccine (n=229) Placebo (n=763) Vaccine (n=587)
39/471 (8.3) 31/227 (13.7) 115/753 (15.3) 105/579 (18.1) HPV56
32/471 (6.8) 16/228 (7.0) 66/754 (8.8) 56/580 (9.7) HPV59
HPV=human papillomavirus. PCR=polymerase chain reaction.
*Comprises genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
†Positive for ≥1 of the listed HPV types at day 1 on at least 1 required swab or (if obtained) biopsy sample.
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RESEARCHTable 2| Impact of quadrivalent HPV vaccine on incidence of subsequent HPV related disease* among women who had undergone cervical
surgery
% reduction (95% CI) in
rate with vaccine
Placebo (n=763) Vaccine (n=587)
End point Rate‡
No of women with a
lesion† Rate‡
No of women with a
lesion†
HPV related disease irrespective of causal HPV type
46.2 (22.5 to 63.2) 12.2 94/593 6.6 45/475 Any disease:
48.3 (19.1 to 67.6) 8.2 65/592 4.3 30/474 Cervical intraepithelial neoplasia
grade I or worse
63.0 (10.3 to 86.6) 2.6 22/589 1.0 7/474 Genital warts
26.5 (−59.5 to 67.5) 2.3 19/589 1.7 12/474 Vulvar or vaginal intraepithelial
neoplasia grade I or worse
64.9 (20.1 to 86.3) 3.1 26/592 1.1 8/474 Cervical intraepithelial neoplasia
grade II or worse
73.5 (3.4 to 95.2) 1.5 13/592 0.4 3/474 Cervical intraepithelial neoplasia
grade III or worse
30.1 (−259.1 to 89.2) 0.6 5/589 0.4 3/474 Vulvar or vaginal intraepithelial
neoplasia grade II or worse
Disease related to vaccine HPV types (6, 11, 16, or 18)
79.1 (49.4 to 92.8) 3.9 33/593 0.8 6/475 Any disease:
74.2 (−24.8 to 97.3) 1.1 9/592 0.3 2/474 Cervical intraepithelial neoplasia
grade I or worse
89.0 (54.9 to 98.7) 2.5 21/589 0.3 2/474 Genital warts
61.3 (−116.7 to 96.2) 0.7 6/589 0.3 2/474 Vulvar or vaginal intraepithelial
neoplasia grade I or worse
61.3 (−382.4 to 99.3) 0.4 3/592 0.1 1/474 Cervical intraepithelial neoplasia
grade II or worse
NA 0.0 0/592 0.0 0/474 Cervical intraepithelial neoplasia
grade III or worse
61.2 (−383.1 to 99.3) 0.4 3/589 0.1 1/474 Vulvar or vaginal intraepithelial
neoplasia grade II or worse
HPV=human papillomavirus.
*Any HPV related disease detected ≥60 days after surgery.
†Number of women with at least one follow-up visit for the respective end point after surgery. A woman is counted only once for each end point (that is, once in
each row) but may have developed more than one end point (and so may appear in more than one row).
‡Cases per 100 person years at risk.
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RESEARCHTable 3| Impact of quadrivalent HPV vaccine on incidence of subsequent cervical intraepithelial neoplasia grade I or worse* associated
with 10 tested non-vaccine HPV types among women who had undergone cervical surgery
% reduction (95% CI) in rate
with vaccine
Placebo (n=763) Vaccine (n=587)
HPV type Rate‡
No of women with a
lesion† Rate‡
No of women with a
lesion†
42.5 (−5.9 to 69.8) 4.1 34/592 2.4 17/474 Any tested non-vaccine
type:
56.6 (3.4 to 82.3) 2.9 24/592 1.2 9/474 HPV types 31, 33, 45,
52, or 58
88.4 (18.6 to 99.7) 1.2 10/592 0.1 1/474 HPV31
22.1 (−579.7 to 93.5) 0.3 3/592 0.3 2/474 HPV33
−76.3 (−2010.8 to 79.8) 0.2 2/592 0.4 3/474 HPV35
−16.8 (−772.3 to 84.4) 0.4 3/592 0.4 3/474 HPV39
100.0 (−76.2 to 100.0) 0.5 4/592 0.0 0/474 HPV45
83.4 (−29.1 to 99.6) 0.8 7/592 0.1 1/474 HPV51
41.7 (−87.1 to 84.4) 1.2 10/592 0.7 5/474 HPV52
68.2 (−20.2 to 94.3) 1.3 11/592 0.4 3/474 HPV56
76.6 (−108.9 to 99.5) 0.6 5/592 0.1 1/474 HPV58
61.1 (−384.9 to 99.3) 0.3 3/592 0.1 1/474 HPV59
HPV=human papillomavirus.
*Cervical intraepithelial neoplasia detected ≥60 days after surgery.
†Number of women with at least one follow-up visit for the respective end point after surgery. A woman is counted only once for each end point (that is, once in
each row) but may have developed more than one end point (and so may appear in more than one row).
‡Cases per 100 person years at risk.
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RESEARCHTable 4| Impact of quadrivalent HPV vaccine on incidence of subsequent HPV related disease among women who had a diagnosis of vulvar
or vaginal disease*
% reduction (95% CI) in
rate with vaccine
Placebo (n=475) Vaccine (n=229)
End point Rate‡
No of women with a
lesion† Rate‡
No of women with a
lesion†
HPV related disease irrespective of causal HPV type
35.2 (13.8 to 51.8) 31.0 163/422 20.1 70/211 Any disease:
46.3 (22.0 to 63.7) 18.2 110/421 9.8 39/210 Cervical intraepithelial neoplasia
grade I or worse
35.6 (−11.9 to 64.3) 7.2 47/413 4.7 19/209 Genital warts
18.4 (−31.1 to 50.3) 8.4 54/413 6.9 28/209 Vulvar or vaginal intraepithelial
neoplasia grade I or worse
40.8 (−14.6 to 71.3) 5.1 35/421 3.0 13/210 Cervical intraepithelial neoplasia
grade II or worse
18.5 (−82.5 to 65.9) 2.8 20/421 2.3 10/210 Cervical intraepithelial neoplasia
grade III or worse
23.5 (−63.3 to 66.4) 3.4 23/413 2.6 11/209 Vulvar or vaginal intraepithelial
neoplasia grade II or worse
Disease related to vaccine HPV types (6, 11, 16, or 18)
64.4 (41.6 to 79.3) 13.8 84/422 4.9 20/211 Any disease:
71.8 (39.5 to 88.5) 6.6 44/421 1.9 8/210 Cervical intraepithelial neoplasia
grade I or worse
60.4 (19.1 to 82.3) 5.9 39/413 2.4 10/209 Genital warts
54.5 (−16.5 to 85.0) 3.1 21/413 1.4 6/209 Vulvar or vaginal intraepithelial
neoplasia grade I or worse
57.7 (−17.0 to 87.7) 2.7 19/421 1.1 5/210 Cervical intraepithelial neoplasia
grade II or worse
25.8 (−131.8 to 79.8) 1.5 11/421 1.1 5/210 Cervical intraepithelial neoplasia
grade III or worse
63.0 (−34.8 to 93.2) 1.9 13/413 0.7 3/209 Vulvar or vaginal intraepithelial
neoplasia grade II or worse
HPV=human papillomavirus.
*Any HPV related disease detected ≥60 days after diagnosis of genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
†Number of women with at least one follow-up visit for the respective end point after surgery. A woman is counted only once for each end point (that is, once in
each row) but may have developed more than one end point (and so may appear in more than one row).
‡Cases per 100 person years at risk.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1401 doi: 10.1136/bmj.e1401 (Published 27 March 2012) Page 12 of 14
RESEARCHFigures
Fig 1 Study design for assessing effect of quadrivalent HPV vaccine on incidence of subsequent HPV related disease
among women who had undergone surgery for cervical disease or who were diagnosed with vulvar or vaginal disease.
Subsequent disease was measured from 60 days after surgery or diagnosis
Fig 2 Participant flow through study
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RESEARCHFig 3 Incidence of HPV related disease detected ≥60 days after cervical surgery or diagnosis of vulvar or vaginal disease
among women who did not receive quadrivalent HPV vaccine (that is, placebo recipients)
Fig 4 Time to detection of any HPV related disease (A) or vulvar or vaginal disease (B) after cervical surgery; and of any
HPV related disease (C) or any cervical disease (D) after diagnosis of vulvar or vaginal disease. Case counting began 60
days after surgery or diagnosis
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